Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARRIVAL tezepelumab background therapy reduction study in severe asthma
2024-512113-41-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of tezepelumab in severe asthma (2 arms), sponsored by AstraZeneca. Primary endpoint: Proportion of patients who reduced their SYMBICORT daily maintenance dose without loss of asthma control at Week 56. Planned start Nov 2024; status: authorised.
02
Drugs
03
Conditions
severe asthma
Beyond the preview
Go deeper on 2024-512113-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512113-41-00.